Barely Significant
← all excerpts

RUNAT-BI: A Ruthenium(III) Complex as a Selective Anti-Tumor Drug Candidate against Highly Aggressive Cancer Cell Lines.

Cancers (Basel) · 2022 · PMC9817854 · PMID 36612065

1
hedged sentence
closest p
boldest claim

The sentences

Our results indicated an increase in BAX and CASPASE-3 in most cell lines treated with Runat-BI compared with control samples ( Figure 5 A,B), although this did not reach statistical significance as analyzed by t -test ( p -value 0.2 for BAX and 0.19 for CASPASE-3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.